All In Biotech

Drug Trial Radar · NCT05707949

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 Years of Age With Migraine

Last checked: Nov 20, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

650

Planned (sponsor's estimate)

Start

Jun 5, 2023

Primary completion

Apr 2032

Study completion Apr 2032

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for participants less than 18 years of age. The main goal of the study is to evaluate the long-term safety and tolerability of atogepant in pediatric participants between the ages of 6 and 17 with migraine. Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of migraine. This is a Phase 3, open-label study of atogepant in participants with a history of migraine. Participants must have completed participation in another study of atogepant (lead-in study). Participants must have 4 to 14 migraine days and less than 15 headache days for episodic migraine, and \>= 15 headache days and \>= 8 migraine days for chronic migraine in the 4-week screening electronic diary (eDiary; similar to a smart phone). Around 650 participants will be enrolled in the study at approximately 100 sites worldwide. Atogepant is a tablet taken once a day by mouth. Participants between the ages of 12 and 17 will receive high dose atogepant for 52 Weeks. Participants between the ages of 6 and 11 will receive an atogepant dose determined in the lead-in study for 52 Weeks. There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

Conditions

  • Migraine Prophylaxis

Interventions

  • AtogepantDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse Events (AEs)Time frame: Up to 56 Weeks
  2. Percentage of Participants with Potentially Clinically Significant Lab ValuesTime frame: Up to 52 Weeks
  3. Percentage of Participants with Potentially Clinically Significant Clinical 12-lead Electrocardiogram (ECG)Time frame: Up to 52 Weeks
  4. Percentage of Participants with Potentially Clinically Significant Vital Sign ParametersTime frame: Up to 52 Weeks
  5. Percentage of with Participants with Treatment-Emergent Suicidal Ideations with Intent, with or without a Plan (i.e., Type 4 or 5 on Columbia-Suicide Severity Rating Scale [C-SSRS]), or any Suicidal BehaviorsTime frame: Up to 52 Weeks
  6. Percentage of Participants with Change in Menstrual Cycle (Female Participants Only)Time frame: Up to 52 Weeks
  7. Change from Baseline in Tanner Staging ScoreTime frame: Baseline (Week 0) through Week 52
  8. Change from Baseline in Behavior Rating Inventory of Executive Function, 2nd Edition (BRIEF 2) questionnaireTime frame: Baseline (Week 0) through Week 52

Locations

86 sites in 16 countries. Site status is shown where the registry gives one.

  • Rehabilitation & Neurological Services /ID# 250910

    Huntsville, Alabama

  • Preferred Research Partners /ID# 250937

    Little Rock, Arkansas

  • Advanced Research Center /ID# 251616

    Anaheim, California

  • Sunwise Clinical Research /ID# 250913

    Lafayette, California

  • Alliance for Research Alliance for Wellness /ID# 250911

    Long Beach, California

  • Excell Research, Inc /ID# 251611

    Oceanside, California

  • Lumos Clinical Research Center /ID# 251608

    San Jose, California

  • Advanced Neurosciences Research, LLC /ID# 250925

    Fort Collins, Colorado

  • Northwest Florida Clinical Research Group, LLC /ID# 251614

    Gulf Breeze, Florida

  • Advanced Research Institute of Miami /ID# 250916

    Homestead, Florida

  • My Preferred Research LLC /ID# 250931

    Miami, Florida

  • Asclepes Research Centers - Spring Hill /ID# 250912

    Spring Hill, Florida

  • Coastal Georgia Child Neurology /ID# 250938

    Brunswick, Georgia

  • Deaconess Clinic - Gateway Health Center /ID# 250923

    Newburgh, Indiana

  • College Park Family Care Center Overland Park /ID# 251609

    Overland Park, Kansas

  • Michigan Headache & Neurological Institute (MHNI) /ID# 250920

    Ann Arbor, Michigan

  • Proven Endpoints LLC /ID# 258083

    Ridgeland, Mississippi

  • Cognitive Clinical Trials (CCT) - Papillion /ID# 251610

    Papillion, Nebraska

  • Goryeb Children's Hospital /ID# 250934

    Morristown, New Jersey

  • Dent Neurosciences Research Center, Inc. /ID# 250915

    Amherst, New York

  • Modern Migraine MD /ID# 258082

    New York, New York

  • Headache Wellness Center /ID# 251612

    Greensboro, North Carolina

  • Patient Priority Clinical Sites, LLC /ID# 250922

    Cincinnati, Ohio

  • CincyScience /ID# 250935

    West Chester, Ohio

  • Lynn Institute of Oklahoma City /ID# 250926

    Oklahoma City, Oklahoma

  • Access Clinical Trials, Inc. /ID# 250914

    Nashville, Tennessee

  • FutureSearch Trials of Neurology /ID# 251613

    Austin, Texas

  • 3A Research - East El Paso /ID# 250909

    El Paso, Texas

  • Earle Research /ID# 250908

    Friendswood, Texas

  • Family Psychiatry of The Woodlands /ID# 250936

    The Woodlands, Texas

  • ClinPoint Trials /ID# 250942

    Waxahachie, Texas

  • Pantheon Clinical Research /ID# 251615

    Bountiful, Utah

  • Highland Clinical Research /ID# 250924

    Salt Lake City, Utah

  • Office of Maria Ona /ID# 250939

    Franklin, Virginia

  • Core Clinical Research /ID# 250932

    Everett, Washington

  • AZ Sint-Jan Brugge /ID# 247527

    Bruges, Belgium

  • Uza /Id# 247885

    Edegem, Antwerpen, Belgium

  • Stollery Children's Hospital /ID# 251426

    Edmonton, Alberta, Canada

  • Montreal Children's Hospital /ID# 250649

    Montreal, Quebec, Canada

  • Herlev Hospital /ID# 247725

    Herlev, Capital Region, Denmark

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.